David Schenkein

As a hematologist and medical oncologist for over 30 years, David Schenkein has spent his career trying to positively impact the lives of patients and their families in need – as a physician, through drug development, and as an investor in the next generation of health startups. Dr. Schenkein co-leads GV’s life science investment team, where his interests include therapeutics, diagnostics, medical devices, novel care delivery systems and payer innovation.

Before joining GV, Dr. Schenkein spent 10 years as CEO and a member of the Board of Directors at Agios Pharmaceuticals, where he remains as a Director. He also served as Senior Vice President of Clinical Hematology/Oncology at Genentech. There, Dr. Schenkein was responsible for numerous successful oncology drug approvals and led the medical and scientific strategies for their BioOncology portfolio. While at Genentech, he also served as an adjunct Clinical Professor of Medical Oncology at Stanford University School of Medicine. Before Genentech, Dr. Schenkein was the Senior Vice President of Clinical Research at Millennium Pharmaceuticals, overseeing the clinical development and worldwide approval of Velcade®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkin’s lymphoma.

Dr. Schenkein currently serves as an Adjunct Attending Physician in Hematology at Tufts Medical Center and is on the Board of Directors of Denali Therapeutics, Agios Pharmaceuticals, Treeline Biosciences, Prime Medicine, Aera Therapeutics and Leyden Labs.

Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.